Medullary thyroid carcinoma (MTC) is a rare human tumor aecting the calcitonin-secreting c-cells of the thyroid. Here we report that two independent strains of transgenic mice expressing a Polyomavirus (Py) truncated middle-T antigen (DMT), consisting of the aminoterminal 304 amino acids, and the full length Py small-T antigen, developed multifocal bilateral MTCs with 100% penetrance. Occasionally one strain also developed mammary and bone tumors. Furthermore, ospring from both transgenic lines displayed pronounced waviness of the whiskers and fur, previously associated with defective epidermal growth factor receptor signaling. Transgene transcription, driven by the homologous early promoter/ enhancer, and the corresponding translation products were detected in tumors and in many other organs which did not develop pathologies. The subcellular distribution of DMT and its interactions with the adapter proteins of the SHC family have also been analysed. Our study describes a novel murine model of MTC and provides evidence that the N-terminal 304 amino acid fragment of Py middle-T antigen, possibly in co-operation with small-T antigen, acts as a potent oncogene in c-cells of the thyroid.
Introduction
The tumorigenic potential of Polyomavirus (Py) is localized to the early region of its genome which encodes three proteins: large-T (LT), middle-T (MT) and small-T (ST) antigen. Py early genes have been used together or separately in a transgenic context to dissect the oncogenic potential of this DNA tumor virus. In contrast to the wide spectrum of tumors obtained after Py infection of newborn or immunocompromized mice (reviewed in Dawe, 1980) , only a limited array of malignant pathologies have been observed in transgenic mice expressing Py T-antigens (reviewed in Kiefer et al., 1994) .
Several studies on transgenic models led us to unambiguously identify MT as the transforming gene of Py. In particular, these studies have shown that LT can be sucient for the development of a neoplastic phenotype in transgenic mice, although with a long latency (Chalifour et al., 1992; Paquis-Flucklinger et al., 1993; Helseth et al., 1992; Lebel et al., 1995) , while ST is not oncogenic in vivo (Bautch, 1989) . In contrast, MT alone, driven by its natural promoter, causes endotheliomas in transgenic mice within 4 ± 10 weeks after birth (Bautch et al.,1987) . In addition to vascular tumors, bone tumors and lymphangiomas were observed when MT was studied in the context of the entire Py early region (Wang and Bautch, 1991) . Moreover, under the control of heterologous tissue speci®c promoters, MT has been shown to induce tumors in a variety of tissues. Under these conditions, MT has been shown to transform mammary gland (Guy et al., 1992) , urogenital and prostatic epithelium (Tehranian et al., 1996) and even a wider organ spectrum including salivary, mammary and thyroid gland (Rassoulzadegan et al., 1990) .
Here we report that transgenic mice expressing the 75% N-terminal fragment of MT antigen and the full length ST antigen consistently develop medullary thyroid carcinomas (MTC), a rare tumor type aecting the calcitonin (CT)-secreting c-cells of the thyroid. Unexpectedly, the MTC was associated with a second dominant phenotype consisting of waved hair and curly whiskers, very similar to that of the spontaneous mouse mutants wa-1 (Crew, 1933) and wa-2 (McLaren and Bowman, 1969) .
Results

The NBL.Py lineages
The transgene (NBL.Py) was constructed from 1.2 kbp of the Py virus early region under the transcriptional control of its own early promoter (Figure 1, upper panel) . To overcome the in vivo low expression level of wild type Py early regulatory sequences (Krippl et al., 1988) , we cloned the transgene under the control of the enhancer derived from a Py mutant virus (NB11/1) which displays a wide host cell range (Maione et al., 1985; De Simone and Amati, 1987) . Indeed this 0.4 kb Py regulatory fragment has recently been demonstrated to be capable of driving the expression of a reporter gene in a variety of cells of dierent tissue derivation and dierentiation stages (Fimia et al., 1995) . The resulting construct codes for a full length ST, a COOH-terminus truncated MT (DMT), and a truncated LT (Figure 1, lower panel) . The shortened MT polypeptide is fused to an 11-aa hydrophilic tail, generated at the Py early coding DNA-VP1 intron fusion point. This DNA after excision from the vector was injected into mouse fertilized eggs and the resulting mice were screened for the presence of the transgene. Three positive lines of transgenic mice were generated: NBL.Py-12, NBL.Py-14 and NBL.Py-82 (Table 1) . Quantitative Southern blot analysis revealed the presence of tandem repeats of the injected fragment in the range of 1 ± 15 per cell genome (data not shown).
Tumor pathology
Line NBL.Py-12, characterized by a low transgene copy number, showed no pathologic phenotype over a long period of observation. Instead, founders #14 and #82 and all their transgenic progeny exhibited a complex fully penetrant dominant phenotype consisting of MTC and a pronounced waviness of the whiskers and fur (Table 1) . In line NBL.Py-14 overt tumor symptoms appeared at 5 ± 7 months, while in line NBL.Py-82 the symptom onset appeared earlier (3 and 4 months). Most of the tumors reached about 0.5 cm in diameter but in many animals tumors did grow to a size larger than 1.5 cm ®nally causing death by trachea constriction. Although metastases were not observed, the presence of multifocal bilateral thyroid neoplasias indicated that tumors did arise in a polyclonal fashion, further supporting the high oncogenic potential of DMT.
The de®nitive diagnosis of MTC was reached following several criteria. Histopathological study of grossly palpable thyroid tumors demonstrated extensive invasion by tumor cells in®ltrating and compressing pre-existing follicles (Figure 2a ). Several animals from both NBL.Py-14 and -82 lines displayed bilateral c-cell hyperplasia as early as 3 and 1 month of age respectively, in the absence of gross evidence of tumor formation (data not shown). The immunohistochemical analysis of NBL.Py thyroid tumors showed a strongly positive CT immunopositivity in most MTC tumor cells (Figure 2b ). This histological picture is consistent with the identi®cation of these tumors as MTCs, and their morphology and progression resemble that observed in human pathology. Furthermore, an abnormal increase (20 ± 40-fold) of basal CT plasma level, which is a biochemical indication of existing MTC in patients, was found in NBL.Py mice with thyroid tumors (data not shown). Lastly, the expression of a speci®c marker of thyroid c-cells, the Number of females/ males transmembrane tyrosine kinase c-RET protein, was studied in transgenic mouse thyroids. Figure 3 shows results from the Western blot analysis of thyroid tumor extracts immunoprecipitated by an anti-RET antibody. As expected, c-RET protein whose expression is restricted to a subset of c-cells (Tsuzuki et al., 1995) appeared to be virtually absent in normal control thyroids ( Figure 3 ; lane 2) but it was abundantly present in medullary thyroid carcinomas (Figure 3 ; lanes 1, 3 and 4), where the normal glandular tissue was completely replaced by an unstructured mass of ccells.
Sporadically, osteosarcomas and mammary adenocarcinomas have been observed in NBL.Py-14 mice (Figure 2c ). Mammary tumors did arise in six out of 11 (54%) females which had multiple pregnancies, after 6 ± 8 months of age, while they were never observed in transgenic virgin females. This observation suggests that a sustained mammary gland mitogenic stimulation is required for the onset of neoplastic transformation in transgenic mammary epithelial cells. Most of the tumors reached sizes larger than 2 cm in diameter but they never caused animal death. Occasionally, accompanying neurological symptoms in aged females led to the identi®cation of skull osteosarcomas (data not shown). Although the development of mammary and bone tumors only in the NBL.Py-14 transgenic line could be explained by an insertional mutagenesis event, evidence suggests that they are likely induced by the expression of DMT. Firstly, the lack of mammary and bone tumors in NBL.Py-82 line can be ascribed to the fact that the lifespan of these animals is much shorter due to the earlier onset and faster progression of MTC. Moreover in other transgenic systems, mammary (Guy et al., 1992) and bone tumors (Wang and Bautch, 1991) were ascribed to the Py MT transforming activity.
NBL.Py mice display wavy hair
Surprisingly, the most precocious phenotype that distinguished NBL.Py mice from normal littermate was a pronounced waviness of the hair and whiskers. Hair and whiskers waviness was most evident shortly after birth and during the ®rst weeks of age, while in were immunoprecipitated with an anti-RET polyclonal antibody (Santoro et al., 1994) . c-RET protein was detected in tumoral lesions of 4 month-old mouse from line #82 (lane 1) and 6 monthold mouse from line #14 (lanes: 3 and 4) but not in nontransgenic thyroid glands pooled from 12 mice of 5 months of age (lane 2). A mouse cell line overexpressing c-RET protein was used as a positive control (lane 5). The positions of the two c-RET forms (145 kD and 160 kD) are indicated older NBL.Py animals the coat appeared almost normal. Nonetheless, NBL.Py mice remained easily distinguishable throughout their life solely on the basis of their coat. Microscopic examination of skin from middorsal region of NBL.Py 12 day-old mice revealed a disorganized arrangement of hair follicles throughout the dermal layer representing the structural basis for the unusual appearance of NBL.Py coat (Figure 4a and  b) . Moreover, many of heterozygous NBL.Py mice from both lineages displayed eye defects including super®cial opacity and discharging even if with variable penetrance and expressivity (data not shown).
Intriguingly, the coat and eye alterations exhibited by these animals were remarkably similar to that of recessive mouse mutations wa-1 and wa-2. Recently, it has been shown that the molecular basis of the wa-1 and wa-2 phenotype is a mutation in the transforming growth factor a (TGFa) (Luetteke et al., 1993; Mann et al., 1993) and epidermal growth factor receptor (EGF-R) (Luetteke et al., 1994; Fowler et al., 1995) gene respectively.
Expression of transgene RNA
The expression pattern of the transgene was analysed at both the RNA and protein level. Total RNAs were isolated from a variety of tissues from adult healthy transgenic mice and from hyperplastic or carcinoma bearing thyroids, from both lineages. Total messengers were analysed by RNase protection assay using a riboprobe spanning the last 260 nucleotides of the cloned Py early region ( Figure 5, lower diagram) . The results showed that protected transcripts of the expected size were present in almost all analysed tissues, both in pretumoral tissues and in organs in which tumors were never observed ( Figure 5 ; upper panel). The transgene expression was widespread and particularly high in hyperplastic thyroids and in thyroid tumors. The expression was also high in unaected tissues such as muscle and kidney, thus suggesting that the tumor phenotype can be due to the combined eect of threshold transgene expression and its tissue-speci®c oncogene properties.
Expression of transgene products
Since our probe in the RNase protection assay did not allow for the identi®cation of the individual Py early transcripts, we assessed the presence of PyT-proteins in tumors to identify unambiguously each of these species (Figure 6 ). In thyroid tumors we found the expression of a full length ST (22 kDa) and a carboxyl-terminus truncated MT polypeptide (40 kDa). In all transgenic tumors analysed, the product of the LT coding sequence that would produce a shortened 30 kDa LT antigen, was undetectable. This absence is possibly due to the instability of its shortened RNA and/or polypeptide. Furthermore we consistently observed the expression of a 28/26 kDa doublet ( Figure 6 ). In Table 2 it is shown that the 28/26 kDa doublet in total lysates from MTCs was recognized by anti-MT speci®c antibodies and displayed an epitope pattern expected for N-terminal fragments of DMT, likely representing its proteolytic cleavage products. The latter ®nding is consistent with the previously reported high proteolytic activity exhibited by Py MT induced tumors (Guy et al., 1992) .
To con®rm that the DMT protein had the structure expected for the truncated moiety, we analysed the antigenic properties of DMT in total lysates from MTCs using a series of well characterized monoclonal antibodies directed against Py MT, as shown in Figure  7 . Table 2 contains data from this analysis supporting the fact that the overall antigenic structure of DMT protein was that of a COOH-terminus truncated MT.
Consistent with the transgene mRNA expression pattern, we found an abundant expression of 40 kDa DMT protein both in unaected organs (muscle, kidney) and in tissues aected by a non proliferative disorder (skin) (data not shown).
Since DMT lacked the 22 hydrophobic amino acid MT putative membrane binding domain (Carmichael et al., 1982) at the carboxyl terminus, we determined the DMT antigen sub-cellular distribution. In cell fractionation experiments, DMT antigen was recovered predominantly in the cytoplasmic fraction. However a sizeable amount (&10%) of 40 kDa DMT was found in the detergent-insoluble membrane fraction; which likely suggests its interaction with some cellular proteins of the membrane cytoskeleton (Elliott et al., 1998) (Figure 8 ).
Since it has been shown that following the phosphorylation of tyrosine 250 by pp60 c-src tyrosinekinase, MT binds the adapter proteins SHC and that this interaction is relevant to the MT transforming mechanism (Dilworth et al., 1994) , we asked whether an association between DMT and SHC takes place in because DMT has a lower anity for p66 than the wild type MT.
Discussion
In the present study we have investigated the in vivo transforming ability of a COOH-terminus truncated form of Py MT under the control of its own early promoter/enhancer. Here we describe the generation of two independent transgenic lines expressing a full length Py ST antigen and a COOH-terminus truncated Py MT antigen comprising amino acid residues 1 ± 304, plus a charged 11-aa tail derived from the construct. These animals eciently expressed the NBL.Py transgene RNA in several tissues consistently with the activity of the ubiquitous PyNB11/1 enhancer. Despite the transgene widespread expression all NBL.Py mice displayed a very peculiar tissue-restricted phenotype consisting of a pronounced waviness of whiskers and fur and medullary thyroid carcinomas.
These results demonstrate that in vivo and in a transgenic context DMT, possibly in co-operation with ST, is able to transform with strikingly high eciency thyroid c-cells and less frequently mammary epithelial cells and osteoblast cells of bone tissue. Since it has been shown that ST is not oncogenic in transgenic models (Bautch, 1989) , it is unlikely that the neoplastic phenotype of NBL.Py mice can be ascribed to ST.
MT transforming activity in vitro is mediated by several interactions with cellular proteins involved with mitogenic signaling. These include the SRC family tyrosine kinases, pp60 c-yes (Kornbluth et al., 1987) , and pp60 c-fyn (Cheng et al., 1988; Horak et al., 1989) . pp60 c-src dependent phosphorylation on tyrosines in MT creates binding sites for the SHC adapter proteins (Campbell et al., 1994; Dilworth et al., 1994) , PI3K (Courtneidge and Heber, 1987) and PLC-g1 (Su et al., 1995) . Substitution of these tyrosines in MT by other amino acids leads to functional defects with greater or lesser eects on cell transformation (Campbell et al., 1994; Courtneidge and Heber, 1987; Dilworth et al., 1994; Su et al., 1995) . This is the ®rst report of a truncated middle-T antigen protein, lacking the PI3K as well as PLC-g1 binding site, retaining an in vivo transforming activity. The ability of DMT to induce tumors was unexpected and not predicted from previous ®ndings on MTinduced transformation in in vitro cell systems (reviewed in Markland and Smith, 1987) . Indeed in vitro data indicate that the COOH-terminus of MT is essential for attachment to membranes and cell transformation (Carmichael et al., 1982; Templeton and Eckhart, 1982) and that MT mutants lacking the PI3K (Courtneidge and Heber, 1987) and, to a lesser extent, the PLC-g1 (Su et al., 1995) binding site are defective in transformation. A number of possibilities exists that could explain this discrepancy. First, it is possible that thyroid c-cells harbor a speci®c mitogenic signaling pathway with which DMT is capable of interacting, despite its cytoplasmic location and lost PI3K activating ability. Established rat ®broblasts, which are the most common cell type used in in vitro studies on MT-induced transformation, possibly lack such a pathway, or are less susceptible to it. Alternatively, it is possible that the relatively low fraction of membrane-associated DMT (&10%) in DMT overexpressing cells is enough to induce an unrestrained growth in thyroid c-cells, even in the absence of an activated PI3K pathway. Our results are in accordance with the previous observation that a Py mutant blocked in signaling through PI3K is still able to induce tumors when inoculated into newborn mice, with only a reduction of 20% in overall tumor frequency with respect to the wild type virus strain (Freund et al., 1992) . Moreover, recent data by Bronson and colleagues (Bronson et al., 1997) strongly suggest a redundancy of MT signaling pathways in inducing tumors at some sites in the whole animal. They describe an in vitro non-transforming Py doublemutant, blocked in binding PI3K as well as SHC, still inducing tumors although with a reduced frequency if compared to the wild type viral strain. As regards DMT membrane targeting in the absence of the MT putative membrane anchoring domain a possible explanation is suggested by the recent work from Elliott and colleagues. In this report it has been shown (Dilworth et al., 1994) , Western blotted and probed with an anti-SHC antibody. Fifty mg of total cell extracts (7) from each sample (A ± C) were tested for SHC expression, as controls. Migration positions for SHC 66 kDa, 52 kDa and 46 kDa species are indicated (arrowhead) that the preservation of a charged amino acid sequence in a MT mutant lacking the hydrophobic transmembrane domain promotes membrane binding through interaction with cytoskeletal structures (Elliott et al., 1998) . Since the C-terminus of DMT is represented by a 11-aa charged tail, derived from the construct, this may be responsible for targeting DMT to the membrane cytoskeleton in a location where it may interfere with cell growth controlling proteins.
At this stage, however, we can only speculate as to the possible mechanism by which DMT induces the ccell tumor phenotype. The ®rst possibility is that, due to its membrane location and complex formation with known MT cellular targets such as SHC and PP2A (data not shown), DMT may promote its eects by a transforming mechanism similar to that of wild type MT. The second possibility is that the cytoplasmic DMT, possibly by binding SHC and negatively interfering with the EGF-induced activation of Ras, may exert a dominant negative eect on the regulation of dierentiation of thyroid c-cells. Two lines of evidence lead us to this hypothesis. The Ras/Raf-1 signal transduction pathway has been shown to induce neuroendocrine dierentiation and to decrease the rate of cell proliferation of a human MTC cell line (Nakagawa et al., 1987; Carson et al., 1995) and of other neural crest-derived cells (Noda et al., 1985) . Further evidence is derived from our observation of the concomitant waved hair phenotype in both lines of NBL.Py mice. The waved phenotype has been shown to result from a down-modulation of the EGF-R signaling pathway either due to the lack of the TGFa ligand (Luetteke et al., 1993; Mann et al., 1993) or to impaired tyrosine kinase activity of the EGF-R itself (Luetteke et al., 1994; Fowler et al., 1995) . These two separate lines of evidence point to a possible role of DMT in interfering in a dominant negative manner with the Ras pathway necessary for the maintenance of the dierentiated phenotype in thyroid c-cells and possibly for proper development of hair in mammals. Work is in progress to test this hypothesis.
Other transgenic (Baetscher et al., 1991; Schulz et al., 1992; Michiels et al., 1997; Johnston et al., 1998) and knockout mice (Harvey et al., 1995) developing MTCs have been described. In common with most of these models, NBL.Py mice have a long latency period (months) for tumor development. However, the NBL.Py is the ®rst animal model with an MTC incidence of 100% at 4 ± 8 months, presenting multifocal and bilateral tumors. The NBL.Py transgenic mice model may oer a valuable tool to study transforming pathways in thyroid c-cells, and provides further insight into Py MT oncogenic properties.
Materials and methods
Construction of the transgene
The 1.2 kbp PvuII fragment of Py genomic DNA, extending from nucleotide 5267 to 1146, was cloned into the SmaI site of the pNBL expression vector polylinker region (Fimia et al., 1995) . This vector was composed of the Py NB11/1 enhancer¯anked by the intron of SV40 VP1. The resulting plasmid was designated pNBL.Py-1.2.
Generation of transgenic mice
Transgenic mice were generated as described by Hogan et al. (1986) . Brie¯y, after excision from pNBL.Py-1.2 plasmid (Sal1 ± AatII) and gel puri®cation the transgene was dissolved in 10 mM Tris pH 7.4 70.1 mM EDTA at a concentration of 5 ± 7 mg/ml and microinjected into (C57 BL/6J x DBA/2) F 2 one-cell embryos. Microinjected embryos were transferred to the oviducts of pseudopregnant foster mothers to complete their development. Transgenic animals were identi®ed by dot blot and Southern blot analysis of genomic DNA extracted from 3 week-old mouse tail biopsies. Brie¯y, genomic DNA was extracted from tail biopsies, digested with the single cut BamHI restriction enzyme and probed with a 32 P-labeled KpnI ± XbaI fragment corresponding to the SV40 VP1 intron of the transgene. Three transgenic founder mice were obtained (#12, #14, #82) and crossed to establish the corresponding transgenic lines. Progeny animals were screened as the founders. These lineages have now been maintained in the heterozygous state for over 2 years.
Transgene RNA analysis
Total RNA was isolated from mouse organs by using a polytron (Pharmacia) to disrupt tissue in 4 M guanidine isothiocyanate. The homogenate was pelleted through a 5.7 M CsCl cushion as previously described (Chirgwin et al., 1979) . The RNA concentration was determined spectrophotometrically and normalized by ethidium bromide staining of agarose gels. The RNAse protection assay was performed by hybridizing 10 mg of total RNAs to an excess of 32 P-labeled antisense RNA probe. The riboprobe was transcribed in vitro with T7 polymerase (Promega) from the pGEM.Py260 construct containing the last 260 bp of the cloned Py early region. After digestion with RNases A and T 1 (Promega) the protected RNA products were analysed by 8 M urea-5% polyacrylamide thin sequencing gels and autoradiography, as previously described (Zinn et al., 1983) .
Protein studies
Total protein extracts were prepared from freshly removed tumors for fractionation experiments and for DMT/SHC complex detection, while mouse organs¯ash-frozen in liquid N 2 were used for DMT and RET expression. Tissues were disrupted by 30 strokes in a Dounce homogenizer in ice-cold immunoprecipitation buer (Tris 20 mM, pH 8; NaCl 137 mM, NP-40 1%; EDTA 10 mM, pH 8; EGTA 5 mM, pH 7; sodium orthovanadate 10 mM; NaF 50 mM, pH 7.2; aprotinin 0.3 TIU/ml; pepstatin 10 mg/ml; leupeptin 25 mg/ml; phenylmethylsulphonyl¯uoride 10 mM; glycerol 10%) and clari®ed by centrifugation (Lipsich et al., 1983) . After immunoprecipitation immunocomplexes were absorbed on protein A coupled to Sepharose beads (protein A Sepharose CL4B; Pharmacia), proteins were blotted onto reinforced nitrocellulose membranes (Schleicher & Schuell) and detection of bound antibodies was performed with the ECL-Western blotting detection kit (Amersham Corp.) according to the manufacturer's instructions.
For Py T-antigen analysis protein samples (2 mg) were immunoprecipitated with Pab762 antibody, kindly provided by Dr S Dilworth (Department of Molecular Medicine, RPMS, London, UK), fractionated on 12.5% SDS-polyacrylamide gels (SDS-PAGE), transferred to nitrocellulose and subjected to Western blot analysis with biotinylated PAb762.
For c-RET expression analysis 2 mg of cell lysates extracted from MTCs were immunoprecipitated with a previously described anti-RET polyclonal antibody (Santoro et al., 1994) and subjected to electrophoretic separation on a 7.5% SDS ± PAGE. Proteins were then blotted and stained with the anti-RET polyclonal antibody.
A commercially available polyclonal anti-SHC antibody (Transduction Laboratories) was used as previously described (Dilworth et al., 1994) to detect DMT/SHC complexes in vivo.
Cell fractions were prepared essentially as previously described (Andrews et al., 1993) . Brie¯y, freshly removed transgenic thyroid tumors were minced with a razor blade. Tumor cells were washed in ice-cold PBS, resuspended in A buer (5 mM Tris HCl, pH 7.4; 2 mM MgCl 2 ; 0.25 M sucrose; 1 mM PMSF; 10 mg/ml pepstatin; 25 mg/ml leupeptin; 0.3 TIU/ml aprotinin) and subjected to Dounce homogenization. Nuclei were removed by centrifugation at 1000 g for 5 min, checked for the absence of unbroken cells, washed with A buer and then lysed in Ripa buer (Figure 8, lane  N) . The supernatant was centrifuged at 100 000 g for 90 min to yield cytosol (Figure 8 , lane C) and membrane (Figure 8 , lane M) fractions; alternatively the 100 000 g pellet was washed with A buer, resuspended in NP-40 buer (50 mM Tris HCl, pH 8; 170 mM NaCl; 0.5% NP-40; 0.3 TIU/ml aprotinin) and centrifuged at 14 000 g for 30 min to yield detergent-insoluble (Figure 8 , lane I) and -soluble (Figure 8 , lane S) fractions. The same proportion of each fraction was mixed with an equal volume of Laemmli sample buer (Laemmli, 1970) , boiled for 3 min and analysed by 12.5% SDS ± PAGE.
Histology and immunohistochemical analysis
Thyroid glands and other organs were removed under dissecting microscope. Organs were prepared for histopathological examination by ®xation in 10% buered formalin and embedded in paran. Five mm thick serial sections were processed either for hematoxylin/eosin staining or for speci®c immunohistochemical CT detection. For immunostaining of CT, the peroxydase antiperoxydase method was performed using a rabbit anti-CT detection kit (DAKO Corp.) Abbreviations MTC, medullary thyroid carcinoma; Py, Polyomavirus; LT, large-T antigen; MT, middle-T antigen; ST, small-T antigen; SV40, simian virus 40; CT, calcitonin; H&E, hematoxylin and eosin; PI3K, phosphatidylinositol 3 kinase; PLC-g1, phospholipase C-g1.
